Citius Oncology annual operating cash flow
2022
2022
2023
2023
2024
2025
Citius Oncology Operating Cash Flow Growth & History (CTOR)
Citius Oncology's operating cash flow was −$5.5M for fiscal 2025.
View full Citius Oncology company overviewCitius Oncology annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | −$5.5M | −$5.6M | — |
| 2024 | 2024-09-30 | $126,353 | $126,353 | — |
| 2023 · Dec 31 | 2023-12-31 | −$601,304 | −$553,336 | — |
| 2023 · Sep 30 | 2023-09-30 | $0 | $0 | — |
| 2022 | 2022-12-31 | −$47,968 | — | — |
| 2022 | 2022-09-30 | $0 | — | — |
Citius Oncology quarterly operating cash flow
Q1.23
Q2.23
Q4.23
Q4.23
Q1.24
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | −$2.7M | −$2.7M | — |
| Q2 2026 | 2026-03-31 | −$3.8M | −$3.8M | — |
| Q1 2026 | 2025-12-31 | −$7.4M | — | — |
| Q4 2025 | 2025-09-30 | −$5.5M | — | — |
| Q3 2025 | 2025-06-30 | $0 | $366,106 | — |
| Q2 2025 | 2025-03-31 | $0 | $191,690 | — |
| Q2 2024 | 2024-06-30 | −$366,106 | −$265,850 | — |
| Q1 2024 | 2024-03-31 | −$191,690 | −$22,891 | — |
| Q4 2023 | 2023-12-31 | −$218,777 | — | — |
| Q4 2023 · Sep 30 | 2023-09-30 | −$113,472 | — | — |
| Q2 2023 | 2023-06-30 | −$100,256 | — | — |
| Q1 2023 | 2023-03-31 | −$168,799 | — | — |
Citius Oncology operating cash flow trends
Between the periods ended 2022-09-30 and 2025-09-30, Citius Oncology's operating cash flow decreased from $0 to −$5.5M, a change of −$5.5M. The latest reported quarter, Q3 2026, shows −$2.7M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Citius Oncology source filings ↗Community posts
Citius Oncology’s wholesaler shipments rise sharply while institutional orders grow modestly
Citius Oncology ($CTOR) reported preliminary sales of 792 Lymphir units to US wholesalers for its fiscal fourth quarter of 2026, up 120% from 360 in the preceding quarter. Separately, prescribing centers ordered 950 vials from wholesalers, ...
